ADC Therapeutics to Showcase at Major Investor Conferences
ADC Therapeutics SA (NYSE: ADCT) has announced its participation in two significant investor conferences, focusing on their groundbreaking work in the field of antibody drug conjugates (ADCs). These events will highlight the company's innovative approaches to treating cancers and showcase the advancements they have made in this important healthcare sector.
RBC Capital Markets Global Healthcare Conference
Event Details
The first conference is the RBC Capital Markets Global Healthcare Conference, scheduled for late May. ADC Therapeutics will engage in a fireside chat format, presenting their latest developments and strategic vision. The presentation will feature insights from Chief Executive Officer Ameet Mallik, who will discuss not only the progress of ADC Therapeutics but also the broader implications of ADC technology in patient care.
Details of the RBC conference are as follows:
- Date: Late May
- Time: 10:30 - 10:55 a.m. ET
- Format: Fireside Chat
Jefferies Global Healthcare Conference
Following the RBC event, ADC Therapeutics will also be present at the Jefferies Global Healthcare Conference in June. This session will continue the dialogue on ADC innovations, featuring the same leadership presenting insights into ADC Therapeutics' ongoing research and development initiatives.
Details of the Jefferies conference include:
- Date: Early June
- Time: 9:55 - 10:25 a.m. ET
- Format: Fireside Chat
Accessing Live Presentations
Investors interested in the sessions can catch the live webcasts through the Events & Presentations section on ADC Therapeutics' official website. This digital access ensures that a global audience can engage with the insights shared during these conferences. Following each presentation, recordings will be available for about thirty days, allowing more time for review and dissemination of the information provided.
About ADC Therapeutics
ADC Therapeutics is at the forefront of medical progress, specializing in antibody drug conjugates (ADCs). The company is committed to transforming treatment methodologies for patients grappling with hematologic malignancies and solid tumors. Their pioneering work is reshaping how these conditions are approached, offering patients new avenues for hope and healing.
One of their flagship products, ZYNLONTA (loncastuximab tesirine-lpyl), has achieved important milestones, having received both FDA accelerated approval and conditional approval from the European Commission. It is aimed at treating relapsed or refractory diffuse large B-cell lymphoma after multiple therapies. ADC Therapeutics continues to nurture this product alongside several others currently in clinical trials.
With headquarters located in Biopôle, ADC Therapeutics carries out operations in various regions, continually expanding to nurture innovation and development in the treatment of severe conditions. For ongoing updates and information on their cutting-edge therapies, visiting their official site is recommended.
Frequently Asked Questions
What is the focus of ADC Therapeutics?
ADC Therapeutics specializes in developing antibody drug conjugates to treat various cancers.
When is ADC Therapeutics presenting at the investor conferences?
They will present at the RBC conference in late May and at the Jefferies conference in early June.
Who will be presenting on behalf of ADC Therapeutics?
Chief Executive Officer Ameet Mallik will be the speaker during the presentations.
How can I access the presentations?
The live presentations can be accessed on the Events & Presentations page of ADC Therapeutics' website.
What is ZYNLONTA?
ZYNLONTA is an innovative ADC that has received accelerated approval for treating certain types of lymphoma.
